CA2774081A1 - Peptide clearing agents - Google Patents

Peptide clearing agents Download PDF

Info

Publication number
CA2774081A1
CA2774081A1 CA2774081A CA2774081A CA2774081A1 CA 2774081 A1 CA2774081 A1 CA 2774081A1 CA 2774081 A CA2774081 A CA 2774081A CA 2774081 A CA2774081 A CA 2774081A CA 2774081 A1 CA2774081 A1 CA 2774081A1
Authority
CA
Canada
Prior art keywords
peptide
enzyme
binding
peptides
target location
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2774081A
Other languages
English (en)
French (fr)
Inventor
Paul James Davis
James Alexander Schouten
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mologic Ltd
Original Assignee
Mologic Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mologic Ltd filed Critical Mologic Ltd
Publication of CA2774081A1 publication Critical patent/CA2774081A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CA2774081A 2009-09-23 2010-09-23 Peptide clearing agents Abandoned CA2774081A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0916749.5A GB0916749D0 (en) 2009-09-23 2009-09-23 Peptide cleaning agents
GB0916749.5 2009-09-23
PCT/GB2010/001796 WO2011036457A1 (en) 2009-09-23 2010-09-23 Peptide clearing agents

Publications (1)

Publication Number Publication Date
CA2774081A1 true CA2774081A1 (en) 2011-03-31

Family

ID=41327500

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2774081A Abandoned CA2774081A1 (en) 2009-09-23 2010-09-23 Peptide clearing agents

Country Status (16)

Country Link
US (1) US8846861B2 (https=)
EP (1) EP2470216A1 (https=)
JP (1) JP2013505287A (https=)
KR (1) KR20120084298A (https=)
CN (1) CN102665768B (https=)
AU (1) AU2010299643B2 (https=)
BR (1) BR112012006389A2 (https=)
CA (1) CA2774081A1 (https=)
GB (1) GB0916749D0 (https=)
IL (1) IL218713A0 (https=)
IN (1) IN2012DN02241A (https=)
MX (1) MX2012003565A (https=)
NZ (1) NZ598802A (https=)
SG (1) SG179015A1 (https=)
WO (1) WO2011036457A1 (https=)
ZA (1) ZA201201527B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2435510A (en) 2006-02-23 2007-08-29 Mologic Ltd Enzyme detection product and methods
US9850296B2 (en) 2010-08-10 2017-12-26 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
EP2603520A4 (en) 2010-08-10 2014-02-19 Ecole Polytech ERYTHROCYTE BINDING THERAPEUTICS
US9517257B2 (en) 2010-08-10 2016-12-13 Ecole Polytechnique Federale De Lausanne (Epfl) Erythrocyte-binding therapeutics
US10953101B2 (en) 2014-02-21 2021-03-23 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
SG11201606761RA (en) 2014-02-21 2016-09-29 Ecole Polytecnique Federale De Lausanne Epfl Epfl Tto Glycotargeting therapeutics
US10046056B2 (en) 2014-02-21 2018-08-14 École Polytechnique Fédérale De Lausanne (Epfl) Glycotargeting therapeutics
US10946079B2 (en) 2014-02-21 2021-03-16 Ecole Polytechnique Federale De Lausanne Glycotargeting therapeutics
WO2018232176A1 (en) 2017-06-16 2018-12-20 The University Of Chicago Compositions and methods for inducing immune tolerance
EP3790577A4 (en) 2018-05-09 2022-04-27 The University of Chicago COMPOSITIONS AND METHODS RELATED TO IMMUNTOLERANCE
WO2021155317A1 (en) 2020-01-31 2021-08-05 Avilar Therapeutics, Inc. Asgpr-binding compounds for the degradation of extracellular proteins
KR20240017423A (ko) 2021-05-03 2024-02-07 아빌라 테라퓨틱스, 인크. 이뮤노글로불린 및 다른 단백질의 분해를 위한 강력한 asgpr-결합 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6075010A (en) 1992-06-09 2000-06-13 Neorx Corporation Small molecular weight ligand-hexose containing clearing agents
US4859449A (en) 1987-09-14 1989-08-22 Center For Molecular Medicine And Immunology Modified antibodies for enhanced hepatocyte clearance
US20030068322A1 (en) 1988-04-18 2003-04-10 Immunomedics, Inc. Methods of antibody-directed enzyme-prodrug therapy
EP0538268A4 (en) 1990-05-11 1993-05-12 The University Of Connecticut Targeted protection from cytotoxins
GB9324807D0 (en) 1993-12-03 1994-01-19 Cancer Res Campaign Tech Tumour antibody
US6172045B1 (en) * 1994-12-07 2001-01-09 Neorx Corporation Cluster clearing agents
ATE458499T1 (de) 1995-06-07 2010-03-15 Immunomedics Inc Verbesserte abgabe von diagnostischen und therapeutischen stoffen an einem zielort
GB9524942D0 (en) * 1995-12-06 1996-02-07 Aepact Ltd Drug therapy
CA2270394A1 (en) * 1996-10-31 1998-05-07 Novalon Pharmaceutical Corporation Identification of drugs using complementary combinatorial libraries
GB9624993D0 (en) * 1996-11-30 1997-01-15 Aepact Ltd Tumour therapy
US7138103B2 (en) 1998-06-22 2006-11-21 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6962702B2 (en) * 1998-06-22 2005-11-08 Immunomedics Inc. Production and use of novel peptide-based agents for use with bi-specific antibodies
AU6059699A (en) * 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
DK1379634T3 (en) * 2001-04-20 2018-03-19 The Univ Of Georgia Research Foundation Inc ACTIVE LOCATION INACTIVATORS
JP2009509535A (ja) * 2005-09-27 2009-03-12 アムニクス， インコーポレイテッド タンパク様薬剤およびその使用
EP2050761B1 (en) 2007-10-16 2011-06-29 Toscana Biomarkers S.r.l. Galactosylated peptides, their preparation and use in autoimmune diseases diagnosis

Also Published As

Publication number Publication date
MX2012003565A (es) 2012-08-03
EP2470216A1 (en) 2012-07-04
CN102665768B (zh) 2015-01-21
NZ598802A (en) 2013-10-25
IL218713A0 (en) 2012-05-31
US8846861B2 (en) 2014-09-30
KR20120084298A (ko) 2012-07-27
AU2010299643A1 (en) 2012-03-22
GB0916749D0 (en) 2009-11-04
IN2012DN02241A (https=) 2015-08-21
CN102665768A (zh) 2012-09-12
BR112012006389A2 (pt) 2016-11-22
SG179015A1 (en) 2012-04-27
ZA201201527B (en) 2013-05-29
JP2013505287A (ja) 2013-02-14
AU2010299643B2 (en) 2014-06-26
US20130053543A1 (en) 2013-02-28
WO2011036457A1 (en) 2011-03-31

Similar Documents

Publication Publication Date Title
AU2010299643B2 (en) Peptide clearing agents
JP7116217B2 (ja) Ｍｔ１－ｍｍｐに特異的な二環性ペプチドリガンド
JP7417432B2 (ja) 新規リンカー、その製造方法およびその応用
US12492224B2 (en) Bicyclic peptide ligands specific for PD-L1
CN111741771B (zh) 特异于epha2的双环肽配体
Siegmund et al. Spontaneous isopeptide bond formation as a powerful tool for engineering site-specific antibody-drug conjugates
JPWO2018230257A1 (ja) ＩｇＧ結合ペプチド、及び該ペプチドによる抗体の特異的修飾
CN109689112A (zh) 化学选择性的巯基与烯基或炔基磷酰胺的偶联
AU2016225810A1 (en) Modified Antibody Compositions, Methods of Making and Using Thereof
CA2921260A1 (en) Methods and compositions for prolonging elimination half-times of bioactive compounds
KR20040058229A (ko) 항체 표적화 화합물
US20070122408A1 (en) Fc Labeling for Immunostaining and Immunotargeting
CN107922479A (zh) 用于有效的位点特异性生物缀合的转谷氨酰胺标签
CN107624115A (zh) 肉毒神经毒素特异性捕获剂、组合物、使用方法和制造方法
JP5677454B2 (ja) 細胞内ターゲット結合用二座ペプチドバインダー
US20250270610A1 (en) Improving the Efficiency of PAL-Catalyzed Protein Ligation By A Cascade Enzymatic Scheme
CN120623341A (zh) 用于目标蛋白的多价d-肽化合物
WO2022080385A1 (ja) ペプチド、およびペプチドを用いる抗体の修飾
JP2023549433A (ja) プレターゲットイメージングおよび治療用ｐｎａプローブ
Krzyscik et al. Preparation of site-specific cytotoxic protein conjugates via maleimide-thiol chemistry and sortase A-mediated ligation
WO2026077389A1 (en) Compounds, linker units comprising the same, and uses thereof in treating diseases
Breurken et al. Semi-synthesis of a protease-activatable collagen targeting probe
EP4157308A2 (en) Kappa opioid receptor agonist-therapeutic antigen binding protein conjugate (ktac) compounds

Legal Events

Date Code Title Description
FZDE Discontinued

Effective date: 20160923